LKM-1 elisa kit
Anti-LKM-1 ELISA
Synonyms
LKM-1; Anti-LKM-1 ELISA; Antibodies against liver-kidney microsomes (LKM); LKM-1 elisa kit
Specificity
The microplate is coated with recombinant human cytochrome p450 IID6. No cross reactivities to other autoantigens have been found. Anti-LKM-1 antibodies show a specificity of >99% for autoimmune hepatitis type 2. The sensitivity of anti-LKM-1 antibodies for autoimmune hepatitis type 2 is 84%.
Application Notes
30 min. incubation (RT) + 30 min. (RT) + 30 min. (RT) + 5 min. (RT) = 1 hour, 35 min. total incubation time.
Samples
Serum
Sensitivity
1.0 U/ml
Preparation and Storage
Store at 2-8 degree C
Related Product Information for LKM-1 elisa kit
Intended Uses: This LKM-1 antibody ELISA is a solid phase enzyme immunoassay employing human recombinant cytochrome p450 IID6 for the quantitative and qualitative detection of antibodies against liver-kidney microsomes (LKM) in human serum. For research use only,
Principle of the Assay: Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. The IgG antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The intensity of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the sample.
Background/Introduction: Autoimmune hepatitis (AIH) is a chronic progressive liver disease of unknown origin that responds well to immunosuppressive therapy, but has a poor prognosis if untreated. Early and accurate identification is therefore of great importance. AIH is characterized by histological features of periportal hepatitis in the absense of viral markers, by hypergammaglobulinemia and, in the majority of individuals, by the presence of autoantibodies in serum. Anti-nuclear antibodies (ANA), smooth muscle antibodies (SMA), anti-liver kidney microsomal antibodies (LKM) and antibodies against soluble liver antigen (SLA) are marker autoantibodies for AIH. 52% of AIH individuals are positive for ANA and/or SMA, 20% for SLA and 3% for LKM-1. These antibodies are of test value for AIH but the only autoantibodies highly specific for AIH are SLA. ANA/SMA also occur in 10-15% of individuals with viral hepatitis and other immune-mediated diseases. LKM-1 are also associated with hepatitis C. Three types of LKM antibodies can be distinguished according to the target antigens. LKM-1 antibodies are directed against cytochrome p450 IID6, a 50 kDa cytoplasmic protein found in hepatocytes and renal proximal tubular cells. LKM-2 antibodies are associated with ticrynafen (tienilic acid) -induced hepatitis. The target antigen is cytochrome p450 IIC9, a cytochrome p450 isoenzyme that catalyzes the metabolic oxidation of the drug. LKM-3 antibodies are associated with chronic hepatitis D. The target antigen is UDP-1 glucoronosyl transferase.
Principle of the Assay: Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. The IgG antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The intensity of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the sample.
Background/Introduction: Autoimmune hepatitis (AIH) is a chronic progressive liver disease of unknown origin that responds well to immunosuppressive therapy, but has a poor prognosis if untreated. Early and accurate identification is therefore of great importance. AIH is characterized by histological features of periportal hepatitis in the absense of viral markers, by hypergammaglobulinemia and, in the majority of individuals, by the presence of autoantibodies in serum. Anti-nuclear antibodies (ANA), smooth muscle antibodies (SMA), anti-liver kidney microsomal antibodies (LKM) and antibodies against soluble liver antigen (SLA) are marker autoantibodies for AIH. 52% of AIH individuals are positive for ANA and/or SMA, 20% for SLA and 3% for LKM-1. These antibodies are of test value for AIH but the only autoantibodies highly specific for AIH are SLA. ANA/SMA also occur in 10-15% of individuals with viral hepatitis and other immune-mediated diseases. LKM-1 are also associated with hepatitis C. Three types of LKM antibodies can be distinguished according to the target antigens. LKM-1 antibodies are directed against cytochrome p450 IID6, a 50 kDa cytoplasmic protein found in hepatocytes and renal proximal tubular cells. LKM-2 antibodies are associated with ticrynafen (tienilic acid) -induced hepatitis. The target antigen is cytochrome p450 IIC9, a cytochrome p450 isoenzyme that catalyzes the metabolic oxidation of the drug. LKM-3 antibodies are associated with chronic hepatitis D. The target antigen is UDP-1 glucoronosyl transferase.
Product Categories/Family for LKM-1 elisa kit
Similar Products
Product Notes
The LKM-1 (Catalog #AAA490240) is an ELISA Kit and is intended for research purposes only. The product is available for immediate purchase. 30 min. incubation (RT) + 30 min. (RT) + 30 min. (RT) + 5 min. (RT) = 1 hour, 35 min. total incubation time. Researchers should empirically determine the suitability of the LKM-1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "LKM-1, ELISA Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
